US Stock MarketDetailed Quotes
RAPP Rapport Therapeutics
- 19.060
- +0.500+2.69%
Close Aug 9 16:00 ET
697.15MMarket Cap-11062P/E (TTM)
21.400High17.740Low154.50KVolume17.740Open18.560Pre Close3.04MTurnover1.68%Turnover RatioLossP/E (Static)36.58MShares28.08052wk High2.07P/B175.35MFloat Cap16.55052wk Low--Dividend TTM9.20MShs Float28.080Historical High--Div YieldTTM19.72%Amplitude16.550Historical Low19.692Avg Price1Lot Size
Rapport Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expense | 213.73%20.8M | 229.30%17.09M | 36.18M | 6.63M | 5.19M |
| Selling and administrative expenses | 167.73%5.11M | 255.26%4.59M | --8.18M | --1.91M | --1.29M |
| -General and administrative expense | 167.73%5.11M | 255.26%4.59M | --8.18M | --1.91M | --1.29M |
| Research and development costs | 232.32%15.69M | 220.70%12.5M | --28M | --4.72M | --3.9M |
| Operating profit | -213.73%-20.8M | -229.30%-17.09M | -36.18M | -6.63M | -5.19M |
| Net non-operating interest income expense | 1,112.22%2.68M | 2,320.00%1.82M | 2.53M | 221K | 75K |
| Non-operating interest income | 1,112.22%2.68M | 2,320.00%1.82M | --2.53M | --221K | --75K |
| Non-operating interest expense | ---- | ---- | --0 | ---- | ---- |
| Other net income (expense) | -617.48%-7.39M | -1.12M | -1.03M | ||
| Gain on sale of security | ---- | -617.48%-7.39M | ---1.12M | ---- | ---1.03M |
| Income before tax | -182.74%-18.12M | -268.84%-22.67M | -34.78M | -6.41M | -6.15M |
| Income tax | 0 | 0 | 10K | 2K | 1K |
| Net income | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -6.41M | -6.15M |
| Net income continuous Operations | -182.65%-18.12M | -268.78%-22.67M | ---34.79M | ---6.41M | ---6.15M |
| Minority interest income | |||||
| Net income attributable to the parent company | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -6.41M | -6.15M |
| Preferred stock dividends | |||||
| Other preferred stock dividends | |||||
| Net income attributable to common stockholders | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -6.41M | -6.15M |
| Basic earnings per share | -541.54%-1.7 | -269.97%-0.94 | -1.47 | -0.265 | -0.2541 |
| Diluted earnings per share | -541.54%-1.7 | -269.97%-0.94 | -1.47 | -0.265 | -0.2541 |
| Dividend per share | |||||
| Currency Unit | USD | USD | USD | USD | USD |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
